Stocks and Investing
Stocks and Investing
Mon, April 20, 2020
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Adam Walsh Maintained (ASND) at Strong Buy with Increased Target to $171 on, Apr 20th, 2020
Adam Walsh of Stifel, Maintained "Ascendis Pharma A/S" (ASND) at Strong Buy with Increased Target from $146 to $171 on, Apr 20th, 2020.
Adam has made no other calls on ASND in the last 4 months.
There is 1 other peer that has a rating on ASND. Out of the 1 peers that are also analyzing ASND, 0 agree with Adam's Rating of Hold.
This is the rating of the analyst that currently disagrees with Adam
- David Lebovitz of "Morgan Stanley" Maintained at Buy with Decreased Target to $180 on, Thursday, April 2nd, 2020